Eliem Therapeutics (ELYM) will pause all further development of ETX-155
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Eliem Therapeutics files for IPO as another Seattle-area biotech firm set to go public
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
Seattle neurology startup Eliem Therapeutics raises $60M, two months after landing $80M
May 24, 2021 at 11:03 am
Bob Azelby. (Eliem Photo)
New funding: Eliem Therapeutics raised $60 million to further development of its therapies for pain and depression. The fresh funding comes just two months after Eliem raised a $80 million round.
The pipeline: Founded in 2019, the company has two lead drug candidates in development: ETX-810 for chronic pain and ETX-155 for major depressive disorder, hormone-related mood disorders, and focal onset seizures. Both are in Phase 2a clinical trials.
ETX-810 is described as an investigational non-opioid that uses the palmitoylethanolamide (PEA) pathway to influence neuroinflammation and pain signaling. ETX-155 is an neuroactive steroid that acts as a GABA